BACKGROUND: Suspicion of @entity263 may persist after an initial negative biopsy result, and repeated biopsy is suggested. The authors assessed whether diagnostic follow-up of @entity1 with an initial diagnosis of isolated, @entity5436 ( @entity5436 ) and a prostate biopsy suspicious for @entity5 (PBSM) is needed. METHODS: The frequency of isolated @entity5436 and PBSM was determined in 4057 @entity1 of a population-based screening study who underwent systematic sextant transrectal biopsy. The predictive value for @entity263 of @entity5436 and PBSM was determined by performing repeated biopsies at 6-week interval. The additional predictive value for @entity5 within a screened population was assessed by performing repeated biopsies at a 1-year interval in 462 consecutively recruited @entity1 with an initial benign biopsy result. @entity1 were subjected to a second screening at a 4-year interval. The biopsy and radical @entity5 features were determined. RESULTS: Isolated @entity5436 and PBSM were diagnosed in 0.8% and 2.6% of biopsied @entity1 , respectively. The detection rates on repeated biopsy were 10.0% (3 of 30 @entity1 ) for isolated @entity5436 , 38.7% (36 of 93 @entity1 ) for PBSM, and 11.0% (51 of 462 @entity1 ) for those with initial benign biopsy results. Except for two @entity1 (one with PBSM and one with @entity5436 ), all others remained @entity263 at their second screening. Features of the @entity5 that were detected after PBSM were comparable to those that were detected on initial biopsy, whereas the few @entity5 that were diagnosed after @entity5436 had highly favorable features. CONCLUSIONS: Compared with @entity1 who have PBSM, @entity1 with isolated @entity5436 on initial biopsy are at no greater risk of being diagnosed with @entity263 than if their initial biopsies were assessed as benign only. Moreover, the features of @entity5 that are diagnosed after an evaluation of @entity5436 warrant no early, extensive diagnostic follow-up.

The predictive value for @entity263 of lesions that raise suspicion of concomitant carcinoma: an evaluation from a randomized, population-based study of screening for XXXX .

@entity1 :: ('9606', 'Species') :: ['participants', 'Participants', 'men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['free of prostate carcinoma', 'prostate carcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignant disease', 'prostatectomy tumor', 'malignancy', 'tumors'] @entity5436 :: ('MESH:D019048', 'Disease') :: ['high-grade prostatic intraepithelial neoplasia', 'HPIN']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
